Ocugen Inc
$ 1.24
2.48%
04 Dec - close price
- Market Cap 387,277,000 USD
- Current Price $ 1.24
- High / Low $ 1.25 / 1.20
- Stock P/E N/A
- Book Value 0.01
- EPS -0.22
- Next Earning Report 2026-03-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.64 %
- ROE -2.90 %
- 52 Week High 1.90
- 52 Week Low 0.52
About
Ocugen, Inc. is a forward-looking clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing groundbreaking gene therapies to address various forms of blindness. Utilizing its proprietary technologies and robust strategic partnerships, Ocugen advances a promising pipeline of innovative treatments targeting retinal diseases. With a strong commitment to addressing significant unmet needs in ocular health, the company is strategically positioned to make substantial contributions to the evolving landscape of regenerative medicine and enhance the quality of life for patients suffering from vision loss.
Analyst Target Price
$9.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-04 | 2025-05-12 | 2025-03-31 | 2024-11-08 | 2024-08-08 | 2024-05-14 | 2024-02-07 | 2023-11-09 | 2023-08-21 | 2023-05-05 | 2023-02-28 |
| Reported EPS | -0.07 | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.03 | -0.06 | -0.08 | -0.07 | -0.1 |
| Estimated EPS | -0.056 | -0.06 | -0.06 | -0.0533 | -0.05 | -0.05 | -0.06 | -0.06 | -0.07 | -0.07 | -0.11 | -0.1 |
| Surprise | -0.014 | 0.01 | 0.01 | 0.0033 | 0 | 0.01 | 0.01 | 0.03 | 0.01 | -0.01 | 0.04 | 0 |
| Surprise Percentage | -25% | 16.6667% | 16.6667% | 6.1914% | 0% | 20% | 16.6667% | 50% | 14.2857% | -14.2857% | 36.3636% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.056 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCGN
2025-10-13 18:03:00
Ocugen Inc. (NASDAQ: OCGN) stock is down by over 10% following dismal quarterly losses and concerns about its fiscal health. The article highlights significant profitability struggles, negative margins, and substantial debt, cautioning traders to observe the stock's performance objectively. Despite challenges, the company's path forward involves fiscal restructuring and innovation-driven sales initiatives.
2024-11-07 00:00:00
Ocugen, Inc. announced it secured a new $30 million credit facility from Avenue Venture Opportunities Fund, L.P. The 4-year term facility, fully funded on closing, is intended for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. This financing is expected to extend the company's cash runway into the first quarter of 2026 and support the clinical development of its gene therapies.
2024-10-09 00:00:00
Ocugen, Inc. announced that the U.S. FDA has lifted the clinical hold on its investigational new drug application for the OCU200 Phase 1 clinical trial. OCU200 is a recombinant fusion protein designed to treat diabetic macular edema (DME), a condition affecting approximately 746,000 people in the United States and often refractory to current anti-VEGF therapies. The company aims to explore OCU200 for additional indications like diabetic retinopathy and wet age-related macular degeneration.
2024-08-26 00:00:00
Ocugen, Inc. announced that Health Canada has approved the initiation of its Phase 3 liMeliGhT clinical trial for OCU400 in Canada. OCU400 is a modifier gene therapy for retinitis pigmentosa (RP), aiming to offer a gene-agnostic treatment option for a broad patient population. This expansion into Canada will run in parallel with the U.S. FDA trial, expediting potential treatment availability for approximately 110,000 patients in both countries.
2024-08-08 00:00:00
Ocugen, Inc. reported its second-quarter 2024 financial results and provided a business update, highlighting significant progress in its modifier gene therapy platform, including dosing patients in the OCU400 Phase 3 clinical trial and advancing OCU410 into Phase 2. The company also announced a $32.6 million net cash infusion from a recent public offering, extending its cash runway into Q3 2025. Financials show a reduced net loss per common share compared to the previous year, demonstrating operational improvements.
2024-08-02 00:00:00
Ocugen, Inc. announced the closing of its underwritten public offering of 30,434,783 shares of common stock at $1.15 per share, generating gross proceeds of approximately $35 million. The company plans to use the net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The offering saw participation from a premier mutual fund and leading life sciences investors, with Titan Partners Group acting as the sole book-running manager.
